A trial found that choosing weight medication based on a person's "phenotype" - the main driver of their eating - nearly doubled weight loss (about 16% vs. 9% at a year).
View or Download the PDF
Selection of Antiobesity Medications Based on Phenotypes Enhances Weight Loss - Acosta et al., Obesity (PDF)
Not everyone overeats for the same reason - and this trial showed that matching weight medication to why a person struggles works dramatically better than a one-size-fits-all approach.
Dr. Hammer's 5 Second Takeaways
There are different "obesity phenotypes"
Researchers identified four patterns: hungry brain (you need more food to feel full), emotional hunger (comfort/hedonic eating), hungry gut (hunger returns quickly), and slow burn (a lower metabolic rate).
Most people fit one - some fit more than one
A phenotype was identifiable in about 85% of people; roughly a quarter had two or more, and 15% didn't fit a clear type.
Matching the medication to the phenotype nearly doubled results
Phenotype-guided treatment produced about 1.75x greater weight loss - 15.9% vs. 9.0% at 12 months.
Far more people hit a meaningful loss
79% of the phenotype-guided group lost more than 10% of their weight at a year, versus 34% of the non-guided group.
Obesity is heterogeneous - and treatment can be personalized
The big idea: obesity isn't one disease, and the same medication won't work equally for everyone. Targeting the underlying driver matters.
Put it into action: if you're considering weight medication, work with a provider who looks at why you struggle (hunger, fullness, cravings, metabolism), not one who just prescribes a default.
Nerd-Out
Acosta et al. (Obesity) measured body composition, resting energy expenditure, satiety, satiation, eating behavior, affect, and physical activity in 450 participants to classify four phenotypes - hungry brain (abnormal satiation), emotional hunger (hedonic eating), hungry gut (abnormal satiety), and slow burn (decreased metabolic rate). In a 12-month pragmatic trial (n=312), phenotype-guided pharmacotherapy (phentermine, phentermine/topiramate, bupropion/naltrexone, lorcaserin, liraglutide) yielded 15.9% vs. 9.0% weight loss (difference −6.9%, P<0.001), with 79% vs. 34% achieving more than 10% loss at 12 months.
Go to the Source:
This summary is drawn from "Selection of Antiobesity Medications Based on Phenotypes Enhances Weight Loss: A Pragmatic Trial in an Obesity Clinic" by Acosta and colleagues (Obesity). The full paper is in the linked PDF above.